Literature DB >> 23589174

Inhibition of melanoma growth by small molecules that promote the mitochondrial localization of ATF2.

Tal Varsano1, Eric Lau, Yongmei Feng, Marine Garrido, Loribelle Milan, Susanne Heynen-Genel, Christian A Hassig, Ze'ev A Ronai.   

Abstract

PURPOSE: Effective therapy for malignant melanoma, the leading cause of death from skin cancer, remains an area of significant unmet need in oncology. The elevated expression of PKCε in advanced metastatic melanoma results in the increased phosphorylation of the transcription factor ATF2 on threonine 52, which causes its nuclear localization and confers its oncogenic activities. The nuclear-to-mitochondrial translocation of ATF2 following genotoxic stress promotes apoptosis, a function that is largely lost in melanoma cells, due to its confined nuclear localization. Therefore, promoting the nuclear export of ATF2, which sensitizes melanoma cells to apoptosis, represents a novel therapeutic modality. EXPERIMENTAL
DESIGN: We conducted a pilot high-throughput screen of 3,800 compounds to identify small molecules that promote melanoma cell death by inducing the cytoplasmic localization of ATF2. The imaging-based ATF2 translocation assay was conducted using UACC903 melanoma cells that stably express doxycycline-inducible GFP-ATF2.
RESULTS: We identified two compounds (SBI-0089410 and SBI-0087702) that promoted the cytoplasmic localization of ATF2, reduced cell viability, inhibited colony formation, cell motility, and anchorage-free growth, and increased mitochondrial membrane permeability. SBI-0089410 inhibited the 12-O-tetradecanoylphorbol-l3-acetate (TPA)-induced membrane translocation of protein kinase C (PKC) isoforms, whereas both compounds decreased ATF2 phosphorylation by PKCε and ATF2 transcriptional activity. Overexpression of either constitutively active PKCε or phosphomimic mutant ATF2(T52E) attenuated the cellular effects of the compounds.
CONCLUSION: The imaging-based high-throughput screen provides a proof-of-concept for the identification of small molecules that block the oncogenic addiction to PKCε signaling by promoting ATF2 nuclear export, resulting in mitochondrial membrane leakage and melanoma cell death. ©2013 AACR

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23589174      PMCID: PMC3690798          DOI: 10.1158/1078-0432.CCR-12-2689

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Emerging roles of ATF2 and the dynamic AP1 network in cancer.

Authors:  Pablo Lopez-Bergami; Eric Lau; Ze'ev Ronai
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

3.  Melanoma prognostic model using tissue microarrays and genetic algorithms.

Authors:  Bonnie E Gould Rothberg; Aaron J Berger; Annette M Molinaro; Antonio Subtil; Michael O Krauthammer; Robert L Camp; William R Bradley; Stephan Ariyan; Harriet M Kluger; David L Rimm
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

4.  Selective elimination of fibroblasts from cultures of normal human melanocytes.

Authors:  R Halaban; F D Alfano
Journal:  In Vitro       Date:  1984-05

5.  ATF2 - at the crossroad of nuclear and cytosolic functions.

Authors:  Eric Lau; Ze'ev A Ronai
Journal:  J Cell Sci       Date:  2012-06-08       Impact factor: 5.285

6.  Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.

Authors:  Aaron J Berger; Harriet M Kluger; Ning Li; Eric Kielhorn; Ruth Halaban; Ze'ev Ronai; David L Rimm
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

7.  Understanding melanoma signaling networks as the basis for molecular targeted therapy.

Authors:  Keiran S M Smalley
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

8.  Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types.

Authors:  Jens M Kelm; Nicholas E Timmins; Catherine J Brown; Martin Fussenegger; Lars K Nielsen
Journal:  Biotechnol Bioeng       Date:  2003-07-20       Impact factor: 4.530

9.  Suppressor role of activating transcription factor 2 (ATF2) in skin cancer.

Authors:  Anindita Bhoumik; Boris Fichtman; Charles Derossi; Wolfgang Breitwieser; Harriet M Kluger; Sean Davis; Antonio Subtil; Paul Meltzer; Stan Krajewski; Nic Jones; Ze'ev Ronai
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-28       Impact factor: 11.205

10.  Inhibition of melanoma growth and metastasis by ATF2-derived peptides.

Authors:  Anindita Bhoumik; Lisa Gangi; Ze'ev Ronai
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

View more
  13 in total

Review 1.  ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease.

Authors:  Gregory Watson; Ze'ev A Ronai; Eric Lau
Journal:  Pharmacol Res       Date:  2017-02-15       Impact factor: 7.658

2.  Activating transcription factor 2 expression mediates cell proliferation and is associated with poor prognosis in human non-small cell lung carcinoma.

Authors:  Zhenyu You; Yong Zhou; Yuling Guo; Wenyan Chen; Shaoqing Chen; Xiaolang Wang
Journal:  Oncol Lett       Date:  2015-11-16       Impact factor: 2.967

3.  HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.

Authors:  Michael F Emmons; Fernanda Faião-Flores; Ritin Sharma; Ram Thapa; Jane L Messina; Jurgen C Becker; Dirk Schadendorf; Edward Seto; Vernon K Sondak; John M Koomen; Yian A Chen; Eric K Lau; Lixin Wan; Jonathan D Licht; Keiran S M Smalley
Journal:  Cancer Res       Date:  2019-04-15       Impact factor: 12.701

Review 4.  Pathways and therapeutic targets in melanoma.

Authors:  Emma Shtivelman; Michael Q A Davies; Patrick Hwu; James Yang; Michal Lotem; Moshe Oren; Keith T Flaherty; David E Fisher
Journal:  Oncotarget       Date:  2014-04-15

5.  The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation.

Authors:  Eric Lau; Yongmei Feng; Giuseppina Claps; Michiko N Fukuda; Ally Perlina; Dylan Donn; Lucia Jilaveanu; Harriet Kluger; Hudson H Freeze; Ze'ev A Ronai
Journal:  Sci Signal       Date:  2015-12-08       Impact factor: 8.192

6.  Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy.

Authors:  E Lau; J Sedy; C Sander; M A Shaw; Y Feng; M Scortegagna; G Claps; S Robinson; P Cheng; R Srivas; S Soonthornvacharin; T Ideker; M Bosenberg; R Gonzalez; W Robinson; S K Chanda; C Ware; R Dummer; D Hoon; J M Kirkwood; Z A Ronai
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

7.  Small Molecules Antagonise the MIA-Fibronectin Interaction in Malignant Melanoma.

Authors:  King Tuo Yip; Xue Yin Zhong; Nadia Seibel; Stefanie Pütz; Jasmin Autzen; Raphael Gasper; Eckhard Hofmann; Jürgen Scherkenbeck; Raphael Stoll
Journal:  Sci Rep       Date:  2016-05-06       Impact factor: 4.379

8.  Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1.

Authors:  Zongwei Gao; Qingjuan Shang; Zhaoyun Liu; Chun Deng; Chunbao Guo
Journal:  Oncotarget       Date:  2015-11-03

9.  ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.

Authors:  Anil Prasad; Nagina Khudaynazar; Ramana V Tantravahi; Amanda M Gillum; Benjamin S Hoffman
Journal:  Oncotarget       Date:  2016-11-29

10.  The Multifunctional Protein Kinase C-ε in Cancer Development and Progression.

Authors:  Kirti Jain; Alakananda Basu
Journal:  Cancers (Basel)       Date:  2014-04-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.